首页> 外文OA文献 >BRCA1 Inhibits Membrane Estrogen and Growth Factor Receptor Signaling to Cell Proliferation in Breast Cancer
【2h】

BRCA1 Inhibits Membrane Estrogen and Growth Factor Receptor Signaling to Cell Proliferation in Breast Cancer

机译:BRCA1抑制膜雌激素和生长因子受体信号转导乳腺癌细胞增殖。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BRCA1 mutations and estrogen use are risk factors for the development of breast cancer. Recent work has identified estrogen receptors localized at the plasma membrane that signal to cell biology. We examined the impact of BRCA1 on membrane estrogen and growth factor receptor signaling to breast cancer cell proliferation. MCF-7 and ZR-75-1 cells showed a rapid and sustained activation of extracellular signal-related kinase (ERK) in response to estradiol (E2) that was substantially prevented by wild-type (wt) but not mutant BRCA1. The proliferation of MCF-7 cells induced by E2 was significantly inhibited by PD98059, a specific ERK inhibitor, or by dominant negative ERK2 expression and by expression of wt BRCA1 (but not mutant BRCA1). E2 induced the synthesis of cyclins D1 and B1, the activity of cyclin-dependent kinases Cdk4 and CDK1, and G1/S and G2/M cell cycle progression. The intact tumor suppressor inhibited all of these. wt BRCA1 also inhibited epidermal growth factor and insulin-like growth factor I-induced ERK and cell proliferation. The inhibition of ERK and cell proliferation by BRCA1 was prevented by phosphatase inhibitors and by interfering RNA knockdown of the ERK phosphatase, mitogen-activated kinase phosphatase 1. Our findings support a novel tumor suppressor function of BRCA1 that is relevant to breast cancer and identify a potential interactive risk factor for women with BRCA1 mutations.
机译:BRCA1突变和使用雌激素是乳腺癌发展的危险因素。最近的工作已经确定了定位在质膜上的雌激素受体,可以向细胞生物学发出信号。我们检查了BRCA1对膜雌激素和生长因子受体信号转导乳腺癌细胞增殖的影响。 MCF-7和ZR-75-1细胞显示出对雌二醇(E2)的快速而持续的细胞外信号相关激酶(ERK)活化,而野生型(wt)基本上阻止了雌二醇(Et2),但突变型BRCA1却没有。 E2诱导的MCF-7细胞的增殖受到PD98059(一种特异性ERK抑制剂)或显性负ERK2表达和wt BRCA1表达的抑制(而突变BRCA1则没有)。 E2诱导细胞周期蛋白D1和B1的合成,细胞周期蛋白依赖性激酶Cdk4和CDK1的活性以及G1 / S和G2 / M细胞周期的进展。完整的肿瘤抑制因子抑制了所有这些。 wt BRCA1还抑制表皮生长因子和胰岛素样生长因子I诱导的ERK和细胞增殖。磷酸酶抑制剂和干扰ERK磷酸酶,有丝分裂原激活的激酶磷酸酶1的RNA敲低阻止了BRCA1对ERK和细胞增殖的抑制。我们的发现支持与乳腺癌相关的新型BRCA1抑癌功能,并发现具有BRCA1突变的女性的潜在互动危险因素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号